98 related articles for article (PubMed ID: 16461311)
1. Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy.
Burighel N; Ghezzi S; Nozza S; Del Bianco P; Lazzarin A; Tambussi G; Poli G; De Rossi A
Haematologica; 2006 Feb; 91(2):244-7. PubMed ID: 16461311
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART.
O'Sullivan CE; Peng R; Cole KS; Montelaro RC; Sturgeon T; Jenson HB; Ling PD
J Med Virol; 2002 Jul; 67(3):320-6. PubMed ID: 12116021
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
[TBL] [Abstract][Full Text] [Related]
4. Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial.
de Lastours V; LeGoff J; Brière J; Agbalika F; Boulet T; Lévy Y; Simon F; Aboulker JP; Molina JM
HIV Med; 2014 Jan; 15(1):23-9. PubMed ID: 24007426
[TBL] [Abstract][Full Text] [Related]
5. Changes in blood B cell phenotypes and Epstein-Barr virus load in chronically human immunodeficiency virus–infected patients before and after antiretroviral therapy.
Richard Y; Amiel C; Jeantils V; Mestivier D; Portier A; Dhello G; Feuillard J; Creidy R; Nicolas JC; Raphael M
J Infect Dis; 2010 Nov; 202(9):1424-34. PubMed ID: 20874514
[TBL] [Abstract][Full Text] [Related]
6. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma.
Bossolasco S; Falk KI; Ponzoni M; Ceserani N; Crippa F; Lazzarin A; Linde A; Cinque P
Clin Infect Dis; 2006 Feb; 42(4):e21-5. PubMed ID: 16421782
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents.
Bekker V; Scherpbier H; Beld M; Piriou E; van Breda A; Lange J; van Leth F; Jurriaans S; Alders S; Wertheim-van Dillen P; van Baarle D; Kuijpers T
J Infect Dis; 2006 Nov; 194(9):1323-30. PubMed ID: 17041860
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
[TBL] [Abstract][Full Text] [Related]
10. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma.
Van Baarle D; Wolthers KC; Hovenkamp E; Niesters HG; Osterhaus AD; Miedema F; Van Oers MH
J Infect Dis; 2002 Aug; 186(3):405-9. PubMed ID: 12134237
[TBL] [Abstract][Full Text] [Related]
11. Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2.
Ghezzi S; Pacciarini F; Nozza S; Racca S; Mariani SA; Vicenzi E; Lazzarin A; Veglia F; Tambussi G; Poli G
HIV Med; 2010 May; 11(5):349-52. PubMed ID: 20015219
[TBL] [Abstract][Full Text] [Related]
12. Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection.
Piriou E; van Dort K; Otto S; van Oers MH; van Baarle D
Clin Infect Dis; 2008 Jan; 46(2):313-6. PubMed ID: 18171268
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
14. A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma.
Bonnet F; Jouvencel AC; Parrens M; Leon MJ; Cotto E; Garrigue I; Morlat P; Beylot J; Fleury H; Lafon ME
J Clin Virol; 2006 Aug; 36(4):258-63. PubMed ID: 16762591
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus load in children infected with human immunodeficiency virus type 1 in Uganda.
Petrara MR; Penazzato M; Massavon W; Nabachwa S; Nannyonga M; Mazza A; Gianesin K; Del Bianco P; Lundin R; Sumpter C; Zanchetta M; Giaquinto C; De Rossi A
J Infect Dis; 2014 Aug; 210(3):392-9. PubMed ID: 24550442
[TBL] [Abstract][Full Text] [Related]
16. Increased susceptibility to HIV-1 of peripheral blood lymphocytes in acute infection with Epstein-Barr virus.
Moriuchi M; Moriuchi H
J Med Virol; 2003 Nov; 71(3):343-6. PubMed ID: 12966538
[TBL] [Abstract][Full Text] [Related]
17. Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma.
Fellner MD; Durand K; Correa RM; Redini L; Yampolsky C; Colobraro A; Sevlever G; Teyssié AR; Benetucci J; Picconi MA
Int J Infect Dis; 2007 Mar; 11(2):172-8. PubMed ID: 16931088
[TBL] [Abstract][Full Text] [Related]
18. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
[TBL] [Abstract][Full Text] [Related]
19. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus genome load is increased by therapeutic vaccination in HIV-l carriers, and further enhanced in patients with a history of symptomatic primary infection.
Friis AM; Akerlund B; Gyllensten K; Aleman A; Bratt G; Sandström E; Ernberg I
Vaccine; 2012 Sep; 30(42):6093-8. PubMed ID: 22863659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
